At Bonus Biogroup, we aim to pioneer the future of regenerative medicine. Our groundbreaking technologies and innovative approach are designed to help millions live better and longer lives.
At Bonus Biogroup, we aim to pioneer the future of regenerative medicine. Our groundbreaking technologies and innovative approach are designed to help millions live better and longer lives.
Bonus Biogroup is a clinical-stage biotechnology company developing tissue engineering and cell therapy products. Our research focuses on addressing unmet medical needs related to tissue damage, inflammation, and immune response.
CELL THERAPY
We develop investigational cell therapies that are designed to leverage the natural properties of mesenchymal cells and provide multi-functional therapeutic mechanisms to modulate inflammation and promote tissue repair. These therapies are currently being evaluated in clinical trials.
TISSUE ENGINEERING
We develop an investigational viable tissue engineering approach, focusing on utilizing a combination of patient-derived cells and biomaterials to support bone and tissue regeneration, currently being evaluated in clinical trials.
Bonus Biogroup is a clinical-stage biotechnology company developing tissue engineering and cell therapy products. Our research focuses on addressing unmet medical needs related to tissue damage, inflammation, and immune response.
CELL THERAPY
We develop investigational cell therapies that are designed to leverage the natural properties of mesenchymal cells and provide multi-functional therapeutic mechanisms to modulate inflammation and promote tissue repair. These therapies are currently being evaluated in clinical trials.
TISSUE ENGINEERING
We develop an investigational viable tissue engineering approach, focusing on utilizing a combination of patient-derived cells and biomaterials to support bone and tissue regeneration, currently being evaluated in clinical trials.
I was critically ill with severe respiratory distress due to COVID-19. After participating in a (Phase II) clinical trial evaluating MesenCure, my condition improved, and I was later discharged from the hospital.
Mr. Francis Kaldawy
A Phase III study is planned to further evaluate MesenCure’s safety and efficacy
I was critically ill with severe respiratory distress due to COVID-19. After participating in a (Phase II) clinical trial evaluating MesenCure, my condition improved, and I was later discharged from the hospital”
Mr. Francis Kaldawy
A Phase III study is planned to further evaluate MesenCure’s safety and efficacy
As a physician, I believe in shaping the future of medicine, and Bonus Biogroup is aiming to do just that. Their product, BonoFill, is an engineered tissue designed to treat the most challenging bone defects, with the potential to mark a significant advancement in Orthopedics.
Prof. Nimrod Rozen
Former President of the Israeli Association of Orthopedic Surgeons
Further research is ongoing to assess its safety and efficacy
As a physician, I believe in shaping the future of medicine, and Bonus Biogroup is aiming to do just that. Their product, BonoFill, is an engineered tissue designed to treat the most challenging bone defects, with the potential to mark a significant advancement in Orthopedics
Prof. Nimrod Rozen
Former President of the Israeli Association of Orthopedic Surgeons
Further research is ongoing to assess its safety and efficacy.
MesenCure
An enhanced allogeneic cell therapy product candidate designed to target inflammation and tissue damage.
In a Phase II clinical trial, patients with respiratory distress due to COVID-19 pneumonia receiving MesenCure with the standard-of-care (SOC) had a 68% lower mortality rate, a 57% reduction in the need for invasive ventilation, and a 38% shorter hospital stay (for those with a hospital stay of more than seven days) compared to SOC alone.
A Phase III study is planned to further evaluate MesenCure’s safety and efficacy.
BonoFill
A personalized, viable tissue-engineered bone graft composed of a high-density culture of the patient's own cells.
BonoFill is designed to fit a wide range of bone defect sizes and clinical indications, with the goal of achieving optimal anatomical reconstruction and enabling patients to return to daily function more quickly.
BonoFill is currently being evaluated in advanced clinical trials for its potential to repair bone defects in maxillofacial and orthopedic applications.
MesenCure
An enhanced allogeneic cell therapy product candidate designed to target inflammation and tissue damage.
In a Phase II clinical trial, patients with respiratory distress due to COVID-19 pneumonia receiving MesenCure with the standard-of-care (SOC) had a 68% lower mortality rate, a 57% reduction in the need for invasive ventilation, and a 38% shorter hospital stay (for those with a hospital stay of more than seven days) compared to SOC alone.
A Phase III study is planned to further evaluate MesenCure’s safety and efficacy.
BonoFill
A personalized, viable tissue-engineered bone graft composed of a high-density culture of the patient's own cells.
BonoFill is designed to fit a wide range of bone defect sizes and clinical indications, with the goal of achieving optimal anatomical reconstruction and enabling patients to return to daily function more quickly.
BonoFill is currently being evaluated in advanced clinical trials for its potential to repair bone defects in maxillofacial and orthopedic applications.
"At Bonus Biogroup, we are committed to advancing regenerative medicine by developing tissue engineering and cell therapy products for unmet clinical needs.
We are thankful to have a dedicated team of scientists, technologists, and business partners who have joined us in forging this pioneering path in regenerative medicine"
Dr. Shai Meretzki, CEO and Founder
"At Bonus Biogroup, we are committed to advancing regenerative medicine by developing tissue engineering and cell therapy products for unmet clinical needs.
We are thankful to have a dedicated team of scientists, technologists, and business partners who have joined us in forging this pioneering path in regenerative medicine."
Dr. Shai Meretzki, CEO and Founder
The product candidates mentioned on this website are in the investigational stage and have not been approved by the FDA or any other regulatory authority for commercial use. Clinical trials are ongoing to evaluate their safety and efficacy.
info@bonus-bio.com
+972 (0)73 206 7104
Matam Advanced Technology
